ADC Therapeutics SA (ADCT)

USD 1.21

(-0.82%)

Total Liabilities Summary of ADC Therapeutics SA

ADC Therapeutics SA's latest annual total liabilities in 2023 was 503.03 Million USD , up 14.21% from previous year.
ADC Therapeutics SA's latest quarterly total liabilities in 2024 Q2 was 503.44 Million USD , up 0.21% from previous quarter.
ADC Therapeutics SA reported annual total liabilities of 440.44 Million USD in 2022, down -2.53% from previous year.
ADC Therapeutics SA reported annual total liabilities of 451.88 Million USD in 2021, up 153.6% from previous year.
ADC Therapeutics SA reported quarterly total liabilities of 503.44 Million USD for 2024 Q2, up 0.21% from previous quarter.
ADC Therapeutics SA reported quarterly total liabilities of 521.08 Million USD for 2023 Q3, up 1.01% from previous quarter.

Annual Total Liabilities Chart of ADC Therapeutics SA (2023 - 2016)

Historical Annual Total Liabilities of ADC Therapeutics SA (2023 - 2016)

Year	Total Liabilities	Total Liabilities Growth
2023	503.03 Million USD	14.21%
2022	440.44 Million USD	-2.53%
2021	451.88 Million USD	153.6%
2020	178.18 Million USD	571.74%
2019	26.52 Million USD	9.09%
2018	24.31 Million USD	6.72%
2017	22.78 Million USD	60.64%
2016	14.18 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	502.41 Million USD	-0.12%
2024 Q2	503.44 Million USD	0.21%
2023 Q3	521.08 Million USD	1.01%
2023 Q1	429.98 Million USD	-2.37%
2023 FY	503.03 Million USD	14.21%
2023 Q4	503.03 Million USD	-3.46%
2023 Q2	515.89 Million USD	19.98%
2022 Q1	419.21 Million USD	-7.23%
2022 FY	440.44 Million USD	-2.53%
2022 Q4	440.44 Million USD	3.15%
2022 Q3	426.97 Million USD	5.4%
2022 Q2	405.11 Million USD	-3.36%
2021 Q2	220.46 Million USD	34.65%
2021 Q3	450.67 Million USD	104.42%
2021 Q4	451.88 Million USD	0.27%
2021 FY	451.88 Million USD	153.6%
2021 Q1	163.73 Million USD	-8.11%
2020 Q2	177.54 Million USD	0.0%
2020 Q3	145.46 Million USD	-18.07%
2020 Q1	- USD	-100.0%
2020 FY	178.18 Million USD	571.74%
2020 Q4	178.18 Million USD	22.49%
2019 Q2	22.85 Million USD	0.0%
2019 Q4	26.52 Million USD	0.0%
2019 FY	26.52 Million USD	9.09%
2019 Q1	- USD	-100.0%
2018 Q1	- USD	0.0%
2018 Q3	22.35 Million USD	0.0%
2018 Q4	24.31 Million USD	8.77%
2018 FY	24.31 Million USD	6.72%
2017 FY	22.78 Million USD	60.64%
2016 FY	14.18 Million USD	0.0%

Peer Total Liabilities Comparison of ADC Therapeutics SA

Name	Total Liabilities	Total Liabilities Difference
Alto Neuroscience, Inc.	158.3 Million USD	-217.771%
Annovis Bio, Inc.	17.95 Million USD	-2700.98%
Biohaven Pharmaceutical Holding Company Ltd.	85.23 Million USD	-490.156%
Ginkgo Bioworks Holdings, Inc.	568.19 Million USD	11.468%
Nuvation Bio Inc.	16.36 Million USD	-2974.386%
Nuvation Bio Inc.	16.36 Million USD	-2974.386%
Arcus Biosciences, Inc.	633 Million USD	20.532%
Zymeworks Inc.	116.07 Million USD	-333.371%